California Public Employees Retirement System Boosts Holdings in Agios Pharmaceuticals, Inc. (AGIO)

California Public Employees Retirement System raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 2.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,900 shares of the biopharmaceutical company’s stock after acquiring an additional 800 shares during the quarter. California Public Employees Retirement System owned approximately 0.07% of Agios Pharmaceuticals worth $1,796,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in Agios Pharmaceuticals by 163.9% during the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 1,583 shares in the last quarter. Aperio Group LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $206,000. Parametrica Management Ltd bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $228,000. Janney Montgomery Scott LLC boosted its position in Agios Pharmaceuticals by 9.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 425 shares in the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in Agios Pharmaceuticals by 84.6% during the 2nd quarter. Great West Life Assurance Co. Can now owns 5,543 shares of the biopharmaceutical company’s stock valued at $285,000 after acquiring an additional 2,541 shares in the last quarter. 93.46% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have weighed in on AGIO shares. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 8th. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Finally, Needham & Company LLC lifted their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $75.70.

TRADEMARK VIOLATION WARNING: “California Public Employees Retirement System Boosts Holdings in Agios Pharmaceuticals, Inc. (AGIO)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/11/05/california-public-employees-retirement-system-boosts-holdings-in-agios-pharmaceuticals-inc-agio.html.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at $66.49 on Friday. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million during the quarter, compared to analyst estimates of $10.85 million. During the same period last year, the business earned ($1.63) earnings per share. The business’s revenue was up 26.4% on a year-over-year basis. analysts forecast that Agios Pharmaceuticals, Inc. will post -6.69 earnings per share for the current year.

In related news, CEO David P. Schenkein sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $62.20, for a total value of $373,200.00. Following the completion of the transaction, the chief executive officer now directly owns 6,000 shares in the company, valued at approximately $373,200. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $61.99, for a total transaction of $133,030.54. Following the completion of the transaction, the insider now owns 8,410 shares of the company’s stock, valued at $521,335.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 178,908 shares of company stock valued at $12,147,719. 10.55% of the stock is owned by company insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

What are top analysts saying about Agios Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agios Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit